家畜の疼痛緩和・予防市場：タイプ、供給源、投与方法、対象種別-2025-2030年の世界予測

家畜の疼痛緩和・予防市場は、2024年には36億8,000万米ドルとなり、2025年には39億5,000万米ドル、CAGR 8.30%で成長し、2030年には59億4,000万米ドルに達すると予測されています。

進化する動物の健康管理の現場では、家畜の疼痛緩和と予防に大きな進歩が見られます。動物福祉に対する意識の高まりと、安全で効果的な治療に対する需要の高まりに伴い、業界はより包括的で革新的なソリューションへと着実に移行しています。このサマリーでは、家畜の疼痛管理戦略の現状を深く洞察し、この分野を再構築しつつある課題、機会、手法に焦点を当てています。

利害関係者は、痛みを和らげるだけでなく、その発症を予防する治療法の必要性から、積極的なアプローチで研究開発を進めています。経済的・倫理的な要請が業界の変化を促す中、より的を絞った介入策や、より健康的な家畜集団と持続可能な農業を実現するための科学的ブレークスルーに焦点が当てられています。

このブリーフィングでは、業界における変革の動きと、市場力学を動かす重要なセグメンテーションの洞察を探る。また、こうした技術革新の地理的分布を掘り下げ、こうした変化を先導する企業を検証し、複雑化する市場で競争力を維持しようとする業界リーダーに実用的な提言を行う。

家畜の疼痛緩和・予防市場の変革

近年、新たな科学研究、技術革新、進化する規制の枠組みが拍車をかけ、家畜の疼痛管理状況は大きく変化しています。こうした変化は、痛みの緩和と予防のためのより専門的で効果的なアプローチの採用を加速させています。バイオテクノロジーとデータ解析の進歩により、開業医は疼痛状態をより正確に診断できるようになり、予防と治療の両面を兼ね備えたケア戦略の改善につながりつつあります。

伝統的な対症療法から、痛みの病因をより深く理解する方向への動きは、重要な変化の推進力です。現在、革新的な治療法は、直接的な痛みの症状だけでなく、急性および慢性の不快感の根本的な原因にも対処するように設計されています。このような統合的なアプローチは、より優れた診断と精密医療によって支えられており、ひいては、より的を絞った治療投与を支えています。

さらに、業界の利害関係者は、畜産システムにおける健康管理の基本要素として、予防対策にますます重点を置くようになっています。世界中の規制機関は、より高い福祉基準を提唱し、新たな科学的証拠と政策を整合させています。このような規制改革は、動物福祉に対する消費者の期待の変化とともに、研究開発や新製品開発に多額の投資を行う企業を後押ししています。

こうした変革的動向は、画一的なアプローチから、より細分化されたデータ主導の手法への転換を必要としています。このような変化を受け入れることで、動物医療分野の意思決定者は、治療結果の最適化、治療コストの削減、農場や生産施設における全体的な生産性の向上を図ることができます。

家畜用疼痛緩和ソリューションの主要セグメント分析

家畜の疼痛緩和と予防の市場は高度にセグメンテーションされており、多様な基準が戦略的意思決定のバックボーンを形成しています。重要なセグメンテーション手法のひとつは、痛みのタイプに基づくもので、急性痛と慢性痛の両方のレンズを通して市場を調査します。この2つのカテゴリーを区別することで、業界の専門家は、突然の痛みを経験する動物と、長引く不快感に苦しむ動物の特定のニーズに応える、的を絞った介入策を設計することができます。

セグメンテーションのもう一つの層は、痛みの原因を強調するもので、病気に関連した痛み、怪我に関連した痛み、処置に伴う痛み、手術に伴う痛みなどを詳細に調査します。このような視点は、治療効果のより精緻な分析を容易にするだけでなく、様々な原因に関連する痛みのパターンを特定するのにも役立ちます。例えば、手技や手術に伴う痛みに対応する治療では、迅速な効果発現と持続的な有効性を確保するために、特殊な製剤や投与方法が必要とされることが多いです。

市場セグメンテーションでさらに考慮すべき点は、投与方法です。投与方法には、経口、非経口、局所投与のメカニズムがあります。特に、非経口投与法は筋肉内投与法と静脈内投与法に細分化され、それぞれに臨床適応と運用上の課題があります。このセグメンテーションは、投与しやすさ、生物学的利用能、費用対効果などの要素をバランスさせながら、動物の特定の状態に合わせて治療薬を投与するために不可欠です。

最後に、対象動物種によるセグメンテーションは、疼痛緩和製品を調整する上で極めて重要です。市場分析では、牛、家禽、羊・山羊、豚など、さまざまな動物種で異なるプロファイルが明らかになりました。動物種が異なれば、痛みへの介入に対する生理的反応も異なるだけでなく、安全性と有効性を確保するために独自の剤形や治療レジメンも必要となります。このセグメンテーション・アプローチは、家畜管理の包括的な需要に適応しながらも、種に特化した治療計画を微調整する上で、治療者と製品開発者に役立ちます。

このようなセグメンテーションの洞察は、家畜の疼痛緩和市場の複雑さと、利害関係者の多様な要求を満たす革新的で正確な、オーダーメイドのソリューションの必要性を強調しています。これらのセグメントを十分に理解することで、企業や研究者は課題をよりよく克服し、動物の健康における成長と改善の機会を見出すことができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ストレスによる病気のない高品質の畜産物に対する需要の高まり
    • 増加する世界人口の食生活のニーズを満たすために畜産業を拡大
    • 世界中で動物福祉基準と倫理的な農業慣行に関する意識が高まる
  • 抑制要因
    • 地域によって異なる規制が製品の流通に影響を与える
  • 機会
    • 家畜の痛みの早期発見と管理を確実にするスマート診断ツールの革新
    • 家畜の健康問題に対処するために、天然および有機的な鎮痛ソリューションを活用する
  • 課題
    • 家畜の痛みのレベルを評価し測定することが難しいため、効果的な治療が困難になる
• 市場セグメンテーション分析
  • タイプ：家畜の急性疼痛の増加により、即効性鎮痛剤または局所麻酔剤の必要性が高まっている
  • 対象種：くちばしのトリミングや輸送時のストレスなどの慣行に関連する福祉上の懸念により、家禽の疼痛管理が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 家畜の疼痛緩和・予防市場：タイプ別

• 急性疼痛
• 慢性疼痛

第7章 家畜の疼痛緩和・予防市場：ソース別

• 病気に伴う痛み
• 怪我による痛み
• 処置に伴う痛み
• 手術の痛み

第8章 家畜の疼痛緩和・予防市場投与方法別

• オーラル
• 非経口
  • 筋肉内
  • 静脈内
• 話題

第9章 家畜の疼痛緩和・予防市場対象種別

• 牛
• 家禽
• 羊とヤギ
• 豚

第10章 南北アメリカの家畜の疼痛緩和・予防市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の家畜の疼痛緩和・予防市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの家畜の疼痛緩和・予防市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AdvaCare Pharma USA
• Bimeda Holdings Limited
• Boehringer Ingelheim International GmbH
• Cargill, Incorporated
• Ceva Sante Animale
• Covetrus, Inc.
• Dechra Pharmaceuticals Limited
• Elanco Animal Health Incorporated
• HUVEPHARMA EOOD
• IDEXX Laboratories, Inc
• Merck & Co., Inc.
• Neogen Corporation
• Norbrook Group
• Patterson Vet Supply, Inc.
• Phibro Animal Health Corporation
• Vetoquinol S.A.
• Vetpro Healthcare
• VIRBAC Animal Health India Private Ltd
• Zoetis Services LLC

LIST OF FIGURES

• FIGURE 1. PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET MULTI-CURRENCY
• FIGURE 2. PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET MULTI-LANGUAGE
• FIGURE 3. PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET RESEARCH PROCESS
• FIGURE 4. PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET DYNAMICS
• TABLE 7. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY DISEASE-RELATED PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY INJURY-RELATED PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PROCEDURAL PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SURGICAL PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 43. CANADA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. CANADA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 47. CANADA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 70. CHINA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. CHINA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 74. CHINA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 75. INDIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. INDIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. INDIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 79. INDIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 161. ITALY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ITALY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. ITALY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 165. ITALY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 181. POLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 182. POLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. POLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 185. POLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 186. QATAR PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. QATAR PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. QATAR PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 190. QATAR PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY METHOD OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SIZE, BY TARGET SPECIES, 2018-2030 (USD MILLION)
• TABLE 236. PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 237. PAIN RELIEF & PREVENTION IN LIVESTOCK MARKET, FPNV POSITIONING MATRIX, 2024

The Pain Relief & Prevention in Livestock Market was valued at USD 3.68 billion in 2024 and is projected to grow to USD 3.95 billion in 2025, with a CAGR of 8.30%, reaching USD 5.94 billion by 2030.

The evolving landscape of animal health management has seen significant advancements in pain relief and prevention for livestock. With a heightened awareness of animal welfare and an ever-increasing demand for safe and effective treatments, the industry has steadily moved towards more comprehensive and innovative solutions. This summary provides a deep insight into the current state of pain management strategies for livestock, highlighting the challenges, opportunities, and methodologies that are reshaping the field.

Fostering a proactive approach, stakeholders are aligning their research and development with the need for therapies that not only alleviate pain but also prevent its onset. As economic and ethical imperatives drive change in the industry, the focus has turned to more targeted interventions and scientific breakthroughs that ensure healthier livestock populations and more sustainable agricultural practices.

In this briefing, we explore the transformative shifts within the industry and the critical segmentation insights that drive market dynamics. We also delve into the geographical distribution of these innovations, examine the companies spearheading these changes, and offer actionable recommendations for industry leaders who are committed to maintaining a competitive edge in an increasingly complex market.

Transformative Shifts in the Livestock Pain Management Landscape

Recent years have witnessed transformative shifts in the pain management landscape for livestock, spurred by emerging scientific research, technological innovations, and evolving regulatory frameworks. These shifts have collectively accelerated the adoption of more specialized and effective approaches to pain relief and prevention. Advances in biotechnologies and data analytics are enabling practitioners to diagnose pain conditions more accurately, leading to improved care strategies that are both preventive and curative in nature.

The movement from traditional symptomatic treatments toward a more nuanced understanding of pain etiology is a critical change driver. Innovative therapies are now being designed to address not only the immediate pain symptoms but also the underlying causes of acute and chronic discomfort. This integrated approach is supported by better diagnostics and precision medicine, which in turn supports a more targeted method of treatment administration.

Furthermore, industry stakeholders are increasingly focusing on preventive measures as a fundamental element of health management in livestock systems. Regulatory bodies around the globe are advocating for higher welfare standards, aligning policies with emerging scientific evidence. Such regulatory reforms, along with shifts in consumer expectations regarding animal welfare, have pushed companies to invest heavily in research and new product development.

These transformative trends have necessitated a shift from a one-size-fits-all approach to a more segmented, data-driven methodology. By embracing these changes, decision-makers in the animal health space are better positioned to optimize outcomes, reduce treatment costs, and enhance overall productivity on farms and production facilities.

Key Segmentation Insights in Livestock Pain Relief Solutions

The market for pain relief and prevention in livestock is highly segmented, with diverse criteria forming the backbone of strategic decisions. One critical segmentation approach is based on the type of pain, where the market is examined through the lens of both acute pain and chronic pain. By distinguishing between these two categories, industry professionals can design targeted interventions that cater to the specific needs of animals experiencing sudden pain versus those suffering from prolonged discomfort.

Another layer of segmentation emphasizes the source of pain, with a detailed study across disease-related pain, injury-related pain, procedural pain, and surgical pain. This perspective not only facilitates a more refined analysis of treatment efficacy but also aids in identifying pain patterns linked to various causes. For instance, treatments addressing procedural and surgical pain often require specialized formulations and administration methods to ensure rapid onset and sustained efficacy.

A further consideration in market segmentation is the method of administration. The spectrum of administration techniques covers oral, parenteral, and topical delivery mechanisms. Notably, the parenteral route is subdivided into intramuscular and intravenous methods, each with its own set of clinical indications and operational challenges. This segmentation is essential for aligning the delivery of therapies with the specific conditions of the animal, while also balancing factors such as ease of administration, bioavailability, and cost-effectiveness.

Lastly, segmentation by target species is crucial for tailoring pain relief products. The market analysis reveals distinct profiles across various species including cattle, poultry, sheep and goats, and swine. Different species not only display varied physiological responses to pain interventions but also require unique dosage forms and treatment regimens to ensure both safety and efficacy. This segmentation approach helps practitioners and product developers fine-tune treatment plans that are species-specific yet adaptable to the overarching demands of livestock management.

These segmentation insights underscore the complexity of the livestock pain relief market and the necessity for innovative, precise, and tailored solutions that meet the diverse requirements of stakeholders. Through a thorough understanding of these segments, companies and researchers can better navigate challenges and identify opportunities for growth and improvement in animal health.

Based on Type, market is studied across Acute Pain and Chronic Pain.

Based on Source, market is studied across Disease-Related Pain, Injury-Related Pain, Procedural Pain, and Surgical Pain.

Based on Method of Administration, market is studied across Oral, Parenteral, and Topical. The Parenteral is further studied across Intramuscular and Intravenous.

Based on Target Species, market is studied across Cattle, Poultry, Sheep & Goats, and Swine.

Key Regional Insights in Global Livestock Pain Management

In the realm of livestock pain management, geographical variations play a pivotal role in shaping market dynamics. Market behavior and demand are significantly influenced by factors such as local regulatory policies, economic conditions, and animal farming practices. The Americas have emerged as a robust market segment, driven by advanced healthcare systems and a strong emphasis on high welfare standards. Within this region, modernization of farming practices, coupled with proactive regulatory oversight, has bolstered the adoption of sophisticated pain management solutions.

In Europe, the Middle East, and Africa, stringent regulations and a heightened focus on animal welfare drive a steady increase in investments focused on pain relief and prevention. These regions have seen considerable advancements as government agencies and private organizations collaborate to enforce higher standards and stimulate innovation in animal health products. Outside the established economies, there is also significant growth in emerging markets as awareness of animal health and welfare continues to rise.

Asia-Pacific represents another dynamic region with unique challenges and opportunities. Rapid growth in the livestock sector, driven by increasing protein demand and expanding export markets, necessitates efficient strategies for managing pain and enhancing animal well-being. In this diverse region, traditional practices blend with modern biomedical insights, thereby creating fertile ground for innovations that can be adapted to local needs. Overall, the regional insights suggest that while the basic principles of pain management apply universally, tailored approaches are essential to meet specific regional requirements and market conditions.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation in Livestock Pain Relief

Market innovation in the fields of pain relief and prevention in livestock is propelled by several leading companies. Companies such as AdvaCare Pharma USA and Bimeda Holdings Limited are at the forefront, consistently advancing treatment options through rigorous R&D efforts and strategic partnerships. Boehringer Ingelheim International GmbH, known for its comprehensive portfolio, combines scientific expertise with market intelligence to facilitate the seamless integration of novel therapies into standard care protocols.

Cargill, Incorporated has been instrumental in bridging the gap between research and practical applications in farm management, while Ceva Sante Animale and Covetrus, Inc. continue to drive innovation by aligning product development with on-ground necessities. Dechra Pharmaceuticals Limited and Elanco Animal Health Incorporated further exemplify the industry's commitment to animal welfare by investing in both preventive and curative solutions that are backed by sound clinical research.

Other key players include HUVEPHARMA EOOD, IDEXX Laboratories, Inc., and Merck & Co., Inc., who have contributed significantly to the understanding of pain pathways and therapeutic interventions. Neogen Corporation, Norbrook Group, Patterson Vet Supply, Inc., and Phibro Animal Health Corporation have also made substantial impacts with next-generation products designed to optimize treatment efficacy. Vetoquinol S.A., Vetpro Healthcare, VIRBAC Animal Health India Private Ltd, and Zoetis Services LLC have established leadership positions by continuously pushing the envelope in research, formulation innovation, and global market strategy. Collectively, these companies represent a robust ecosystem wherein advanced research, efficient production, and strategic market deployment work in concert to revolutionize the management of pain in livestock.

The report delves into recent significant developments in the Pain Relief & Prevention in Livestock Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma USA, Bimeda Holdings Limited, Boehringer Ingelheim International GmbH, Cargill, Incorporated, Ceva Sante Animale, Covetrus, Inc., Dechra Pharmaceuticals Limited, Elanco Animal Health Incorporated, HUVEPHARMA EOOD, IDEXX Laboratories, Inc, Merck & Co., Inc., Neogen Corporation, Norbrook Group, Patterson Vet Supply, Inc., Phibro Animal Health Corporation, Vetoquinol S.A., Vetpro Healthcare, VIRBAC Animal Health India Private Ltd, and Zoetis Services LLC. Actionable Recommendations for Industry Leaders in Livestock Pain Management

Industry leaders are in a unique position to drive forward substantial improvements in the domain of livestock pain relief and prevention. First and foremost, investing in robust research and developmental activities is essential. Companies should focus on the cultivation of innovative therapies that are precisely targeted to distinct pain categories, be they acute or chronic. This emphasis on precision will help in addressing the underlying causes of pain, rather than just offering symptomatic relief.

It is important to leverage the growing insights derived from market segmentation. By integrating data on pain type, source, method of administration, and target species, decision-makers can tailor solutions that meet the specific requirements of various livestock segments. For instance, enhancing capabilities in developing products that are highly effective for disease-related pain or formulations optimized for different species can provide a significant competitive advantage in a diverse market.

Regional considerations must not be overlooked. Ignoring the regional nuances in regulation, consumer demand, and farming practices can lead to suboptimal outcomes. Industry leaders should customize their approaches based on economic conditions and local market maturity in areas such as the Americas, Europe, Middle East & Africa, and Asia-Pacific. This tailored strategy should be complemented by strong local partnerships and investments in regional research centers.

Fostering an ecosystem of collaboration between private enterprises, regulatory bodies, and academic institutions is another critical step forward. This collaboration is essential for fostering innovations that are both scientifically rigorous and commercially viable. Additionally, streamlining regulatory approvals and aligning product development with the latest compliance standards can expedite the market entry process and enhance consumer trust.

Finally, maintaining a customer-centric orientation by incorporating feedback from veterinarians, farmers, and other stakeholders can significantly improve product design and service delivery. Effective communication channels and customer engagement strategies will serve to bridge the gap between innovative solution offerings and the practical needs encountered on the ground. By following these recommendations, industry leaders can transform challenges into opportunities and establish a resilient framework for sustained growth in livestock pain management.

Conclusion: Summarizing Advancements in Livestock Pain Relief & Prevention

In summary, the landscape of pain relief and prevention in livestock is undergoing a profound transformation driven by scientific advancements, strategic segmentation, and a global shift towards higher animal welfare standards. The integration of cutting-edge research, targeted therapeutic approaches, and detailed market segmentation has redefined the way industry stakeholders approach pain management. With innovations spanning from acute to chronic pain treatments, and from varied sources such as disease, injury, procedural, and surgical origins, the market is evolving to meet the complex demands of modern farming practices.

Regionally, tailored solutions are emerging as local markets such as the Americas, Europe, Middle East & Africa, and Asia-Pacific display unique characteristics that influence both the demand for and the design of pain relief products. This convergence of global perspectives ensures that pain management practices are both scientifically advanced and deeply rooted in local realities. Meanwhile, leading companies are showcasing the benefits of a rigorous and innovative approach, which not only enhances the efficiency of treatments but also paves the way for sustainable and scalable solutions in animal health.

Ultimately, the current trends highlight an industry in transition - one that is steadily embracing innovation and precision, charting a course towards improved health outcomes for livestock and a more sustainable future for animal care worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for high-quality livestock products free from stress-induced illnesses
    • 5.1.1.2. Expanding livestock farming industry to meet the dietary needs of a growing global population
    • 5.1.1.3. Increasing awareness about animal welfare standards and ethical farming practices worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. Varying regulations across different regions impacting product distribution

• 5.1.3. Opportunities
  • 5.1.3.1. Innovating smart diagnostic tools to ensure early detection and management of pain in livestock populations
  • 5.1.3.2. Leveraging natural and organic pain relief solutions to address health concerns in livestock
• 5.1.4. Challenges
  • 5.1.4.1. Difficulty in assessing and measuring pain levels in livestock complicates effective treatment
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Increasing acute pain in livestock contribute the need for fast-acting analgesics or local anesthetics
  • 5.2.2. Target Species: Rising pain management in poultry due to welfare concerns related to practices such as beak trimming and transport stress
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pain Relief & Prevention in Livestock Market, by Type

• 6.1. Introduction
• 6.2. Acute Pain
• 6.3. Chronic Pain

7. Pain Relief & Prevention in Livestock Market, by Source

• 7.1. Introduction
• 7.2. Disease-Related Pain
• 7.3. Injury-Related Pain
• 7.4. Procedural Pain
• 7.5. Surgical Pain

8. Pain Relief & Prevention in Livestock Market, by Method of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
  • 8.3.1. Intramuscular
  • 8.3.2. Intravenous
• 8.4. Topical

9. Pain Relief & Prevention in Livestock Market, by Target Species

• 9.1. Introduction
• 9.2. Cattle
• 9.3. Poultry
• 9.4. Sheep & Goats
• 9.5. Swine

10. Americas Pain Relief & Prevention in Livestock Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Pain Relief & Prevention in Livestock Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Pain Relief & Prevention in Livestock Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Lidocaine infused bands minimize castration discomfort for young calves
  • 13.3.2. Dopharma launches Dophacyl Avi for poultry pain relief
  • 13.3.3. Panav Biotech launches Maropitine injection
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AdvaCare Pharma USA
• 2. Bimeda Holdings Limited
• 3. Boehringer Ingelheim International GmbH
• 4. Cargill, Incorporated
• 5. Ceva Sante Animale
• 6. Covetrus, Inc.
• 7. Dechra Pharmaceuticals Limited
• 8. Elanco Animal Health Incorporated
• 9. HUVEPHARMA EOOD
• 10. IDEXX Laboratories, Inc
• 11. Merck & Co., Inc.
• 12. Neogen Corporation
• 13. Norbrook Group
• 14. Patterson Vet Supply, Inc.
• 15. Phibro Animal Health Corporation
• 16. Vetoquinol S.A.
• 17. Vetpro Healthcare
• 18. VIRBAC Animal Health India Private Ltd
• 19. Zoetis Services LLC